India Pharma Outlook Team | Wednesday, 03 September 2025
Glenmark Pharmaceuticals has announced its plans to launch Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials, in the United States this September.
The product was determined to be bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection of Eisai, Inc., providing an economical option in the oncology space.
According to IQVIA sales data of the 12 months ending July 2025 Halaven Injection had annual sales of about $66.3 million. Glenmark's generic introduction is expected to create substantial opportunities in this market, which includes both the brand and all approved therapeutic equivalents.
Also Read: Anti-Infectives: How New Research is Shaping Infection Control
Commenting on the launch, Marc Kikuchi, president & business head, North America said, “We are pleased to announce the launch of eribulin mesylate injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials. As the first complex generic in our portfolio, this launch marks both our commitment to growing our portfolio of products within the institutional channel and reinforces our dedication to bring quality and affordable alternatives to market for patients in need.”
Glenmark's also noted its Eribulin Mesylate Injection is only approved for the indications that are included in the label, and is not marketed for all indications of the reference listed drug. Glenmark has a broad global reach across branded, generics, and OTC products, with key focus on therapeutic areas of respiratory, dermatology, and oncology, and has an increasing position in the relevant therapeutic area of oncology. Glenmark's launch indicates the company's strategy to expand their oncology portfolio while also increasing access to the patient community for affordable medicines.
